IACTA Pharmaceuticals careers
IACTA has licensed the rights to NM133, a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye. This unique nanotechnology allows a hydrophobic drug to be encapsulated and delivered to the tissues of the eye with favorable tissue permeation.
IACTA Pharmaceuticals hasn't added any jobs yet
Get notified when IACTA Pharmaceuticals posts new jobs.
Damon Burrows
CEO - IACTA Pharmaceutics
IACTA Pharmaceuticals was established by former key Allergan executives to develop and commercialize innovative eyecare products.
Ptc Therapeutics • United States • $119k – $145k • 3 weeks ago
Tangram Interiors • Dallas • $90k – $100k • 3 weeks ago
Eli Lilly • Indianapolis • $69k – $165k • 3 weeks ago
Sanofi Aventis • Cambridge • 3 weeks ago
Penumbra • California • $95k – $145k • 3 weeks ago
